Valuation
- Market cap
- 104,795,000
- Revenue TTM
- $0
- Net income TTM
- $-147,270,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 2,800,100
- Avg volume
- 747,794
- Day's range
- $2.09 – $2.11
- Shares out
- 50,141,000
- Stochastic %K
- 50%
- Beta
- 0.77
- Analysts
- Hold
- Price target
- $1.85
Company profile
HilleVax, Inc., a clinical-stage biopharmaceutical company, develops and commercializes vaccines in the United States. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. It has a license agreement with Takeda Vaccines, Inc. to develop and commercialize HIL-214 pharmaceutical products. The company was...
Show more
HilleVax, Inc., a clinical-stage biopharmaceutical company, develops and commercializes vaccines in the United States. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. It has a license agreement with Takeda Vaccines, Inc. to develop and commercialize HIL-214 pharmaceutical products. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts. As of September 17, 2025, HilleVax, Inc. operates as a subsidiary of XOMA Royalty Corporation.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 617 213 5054
- Website
- https://www.hillevax.com
- Address
- 321 Harrison Avenue, 5th Fl., Boston, United States
Latest news
No headlines yet.
